Related Experiment Videos
Tolerance to single-dose dactinomycin in combination chemotherapy for solid tumors
Cancer Treatment Reports
|January 1, 1981
Summary
Single-dose dactinomycin (Act D) offers a convenient and effective alternative for treating Ewing's sarcoma and rhabdomyosarcoma. This regimen is as effective and no more toxic than traditional dosing, with manageable side effects.
Area of Science:
- Pediatric Oncology
- Medical Oncology
- Pharmacology
Background:
- Dactinomycin (Act D) is a chemotherapy agent used in treating pediatric sarcomas.
- Traditional administration involves divided daily doses, which can be inconvenient.
- Evaluating alternative dosing regimens is crucial for improving patient care and treatment adherence.
Purpose of the Study:
- To assess the efficacy and toxicity of single-dose dactinomycin (Act D) in pediatric sarcoma patients.
- To compare single-dose Act D with traditional divided dosing in the same patient cohort.
- To evaluate the convenience of single-bolus Act D administration.
Main Methods:
- Retrospective review of 29 patients with Ewing's sarcoma or rhabdomyosarcoma.
- Analysis of 114 courses of single-dose Act D (2 mg/m2) in combination chemotherapy regimens.
- Comparison with 152 courses of combination chemotherapy using doxorubicin instead of Act D in the same patients.
Main Results:
- Single-dose Act D was administered with vincristine, cyclophosphamide, or DTIC, with or without radiotherapy.
- Common side effects included nausea/vomiting (100%), mucositis (25%), thrombocytopenia (16%), and granulocytopenia (18%).
- Skin reactions occurred in 74% of courses with concomitant radiotherapy.
Conclusions:
- Single-bolus dactinomycin (Act D) is a viable alternative to divided daily dosing for pediatric sarcomas.
- The single-dose regimen demonstrates comparable efficacy and toxicity profiles.
- Single-bolus Act D offers improved convenience in administration.